Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127171582 | 12717158 | 2 | F | 2015 | 20160831 | 20160906 | 20160908 | EXP | DE-ABBVIE-16P-062-1715907-00 | ABBVIE | EFFERTH T, SCHOTTLER U, KRISHNA S, ET AL. HEPATOTOXICITY BY COMBINATION TREATMENT OF TEMOZOLOMIDE, ARTESUNATE AND CHINESE HERBS IN A GLIOBLASTOMA MULTIFORME PATIENT: CASE REPORT REVIEW OF THE LITERATURE. ARCH TOXICOL.. 2016 AUG 12;1-14. | 65.00 | YR | F | Y | 0.00000 | 20160908 | OT | COUNTRY NOT SPECIFIED | DE |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127171582 | 12717158 | 1 | PS | VALPROIC ACID. | VALPROIC ACID | 1 | Unknown | U | UNKNOWN | 18081 | |||||||||
| 127171582 | 12717158 | 2 | I | TEMOZOLOMIDE. | TEMOZOLOMIDE | 1 | Oral | U | UNKNOWN | 0 | |||||||||
| 127171582 | 12717158 | 3 | I | LEVETIRACETAM. | LEVETIRACETAM | 1 | Unknown | U | UNKNOWN | 0 | |||||||||
| 127171582 | 12717158 | 4 | I | LEVETIRACETAM. | LEVETIRACETAM | 1 | Unknown | U | UNKNOWN | 0 | |||||||||
| 127171582 | 12717158 | 5 | I | ARTESUNATE | ARTESUNATE | 1 | Unknown | Y | UNKNOWN | 0 | CAPSULE | ||||||||
| 127171582 | 12717158 | 6 | I | COPTIS-KUSH | HERBALS | 1 | Unknown | Y | UNKNOWN | 0 | |||||||||
| 127171582 | 12717158 | 7 | SS | ONDANSETRON | ONDANSETRON | 1 | Unknown | U | UNKNOWN | 0 | |||||||||
| 127171582 | 12717158 | 8 | SS | LORAZEPAM. | LORAZEPAM | 1 | Oral | U | UNKNOWN | 0 | |||||||||
| 127171582 | 12717158 | 9 | SS | CLOBAZAM | CLOBAZAM | 1 | Oral | U | UNKNOWN | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127171582 | 12717158 | 1 | Epilepsy |
| 127171582 | 12717158 | 2 | Glioblastoma multiforme |
| 127171582 | 12717158 | 3 | Epilepsy |
| 127171582 | 12717158 | 5 | Malaria prophylaxis |
| 127171582 | 12717158 | 6 | Product used for unknown indication |
| 127171582 | 12717158 | 7 | Prophylaxis of nausea and vomiting |
| 127171582 | 12717158 | 8 | Epilepsy |
| 127171582 | 12717158 | 9 | Epilepsy |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127171582 | 12717158 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127171582 | 12717158 | Alanine aminotransferase increased | |
| 127171582 | 12717158 | Aspartate aminotransferase increased | |
| 127171582 | 12717158 | Blood lactate dehydrogenase increased | |
| 127171582 | 12717158 | Drug interaction | |
| 127171582 | 12717158 | Gamma-glutamyltransferase increased | |
| 127171582 | 12717158 | Hepatotoxicity | |
| 127171582 | 12717158 | Monocyte count decreased | |
| 127171582 | 12717158 | White blood cell count decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127171582 | 12717158 | 2 | 2014 | 0 | ||
| 127171582 | 12717158 | 5 | 20150920 | 20151020 | 0 |